by GlyTherix | Feb 21, 2023
ANSTO to supply Lutetium-177 for GlyTherix’s Phase Ib therapeutic trial in patients with prostate, pancreatic and bladder cancers Phase Ib basket clinical trial expected to start in late 2023 Sydney, Australia – February 21, 2023 – GlyTherix Ltd, an Australian...
by GlyTherix | Feb 13, 2023
February 10, 2023 – Thanks Mergermarket (an ION group company) for your cover of our exciting news “GlyTherix seeks USD 10m in pre-IPO funding ahead of planned listing in 2024 – CEO”. Our Phase 1b study will be a pivotal event for the company as we develop a vital new...
by GlyTherix | Aug 11, 2022
We are pleased to announce that our key composition of matter patent for GlyTherix Ltd’s proprietary antibody to GPC-1 is now registered in 20 countries including US, Australia, China and Japan as well as several key European countries. The company’s IP estate is...
by GlyTherix | Jul 21, 2022
Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...
by GlyTherix | Jul 15, 2022
Congratulations to Prof Kris Thurecht for the funding of the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR). GlyTherix Ltd is a proud partner organisation and is excited to see Australian radioimmunotherapy technology getting this...
by GlyTherix | Jul 8, 2022
Date, July 8 2022: Sydney. GlyTherix has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab® monoclonal antibody therapies in gastroesophageal cancers. GEMINI, backed by the...
